NeGIO Therapeutics: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
NeGIO Therapeutics
Largest movements
- Current investments -€3.8m
no longer reported in 2025 (was €3.8m)
- Cash +€2.8m
up €2.8m (+171%), from €1.6m to €4.4m
mainly Current investments (+€3.8m) and Investment in fixed assets (net) (+€165,419)
- Receivables within one year +€281,852
up €281,852 (+263%), from €107,012 to €388,864
of which Other amounts receivable: +€341,865
- Formation expenses -€118,083
no longer reported in 2025 (was €118,083)
- Profit (loss) carried forward -€607,875
down €607,875 (-12.9%), from -€4.7m to -€5.3m
- Trade debts -€213,128
down €213,128 (-94.5%), from €225,484 to €12,356
- Tax, wage and social debts -€114,534
no longer reported in 2025 (was €114,534)
of which Remuneration and social security: -€114,390
- Gross operating margin +€1.9m
up €1.9m (+90.5%), from -€2.1m to -€196,240
- Staff costs -€311,254
down €311,254 (-48.1%), from €646,499 to €335,245
- Financial income -€56,702
down €56,702 (-45.8%), from €123,933 to €67,231
- Depreciation -€49,792
down €49,792 (-97.0%), from €51,358 to €1,566
- Financial charges -€28,116
down €28,116 (-89.9%), from €31,290 to €3,174
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €5,699,030 | €4,763,493 | -€935,537 | -16.4% |
| Formation expenses | 20 | €118,083 | - | -€118,083 | |
| Fixed assets | 21/28 | €52,855 | €3,953 | -€48,902 | -92.5% |
| Tangible fixed assets | 22/27 | €50,498 | €3,953 | -€46,545 | -92.2% |
| Plant, machinery and equipment | 23 | €50,498 | €3,953 | -€46,545 | -92.2% |
| Financial fixed assets | 28 | €2,357 | - | -€2,357 | |
| Current assets | 29/58 | €5,528,092 | €4,759,540 | -€768,552 | -13.9% |
| Amounts receivable within one year | 40/41 | €107,012 | €388,864 | +€281,852 | +263% |
| Trade receivables | 40 | €60,013 | - | -€60,013 | |
| Other amounts receivable | 41 | €46,999 | €388,864 | +€341,865 | +727% |
| Current investments | 50/53 | €3,800,000 | - | -€3.8m | |
| Cash at bank and in hand | 54/58 | €1,614,863 | €4,370,676 | +€2.8m | +171% |
| Deferred charges and accrued income | 490/1 | €6,217 | - | -€6,217 | |
| Total equity and liabilities | 10/49 | €5,699,030 | €4,763,493 | -€935,537 | -16.4% |
| Equity | 10/15 | €5,359,012 | €4,751,137 | -€607,875 | -11.3% |
| Contributions | 10/11 | €10,084,984 | €10,084,984 | = | 0.0% |
| Capital | 10 | €246,292 | €246,292 | +€0 | 0.0% |
| Issued capital | 100 | €246,292 | €246,292 | +€0 | 0.0% |
| Contributions outside capital | 11 | €9,838,692 | €9,838,692 | -€0 | 0.0% |
| Share premium | 1100/10 | €9,838,692 | €9,838,692 | -€0 | 0.0% |
| Profit (loss) carried forward | 14 | -€4,725,972 | -€5,333,847 | -€607,875 | -12.9% |
| Amounts payable | 17/49 | €340,018 | €12,356 | -€327,662 | -96.4% |
| Amounts payable within one year | 42/48 | €340,018 | €12,356 | -€327,662 | -96.4% |
| Trade debts | 44 | €225,484 | €12,356 | -€213,128 | -94.5% |
| Suppliers | 440/4 | €225,484 | €12,356 | -€213,128 | -94.5% |
| Taxes, remuneration and social security | 45 | €114,534 | - | -€114,534 | |
| Taxes | 450/3 | €145 | - | -€145 | |
| Remuneration and social security | 454/9 | €114,390 | - | -€114,390 | |
| Remuneration, social security and pensions | 62 | €646,499 | €335,245 | -€311,254 | -48.1% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €51,358 | €1,566 | -€49,792 | -97.0% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals) | 631/4 | €825 | - | -€825 | |
| Other operating charges | 640/8 | - | €20,616 | +€20,616 | |
| Non-recurring operating charges | 66A | - | €118,083 | +€118,083 | |
| Gross operating margin | 9900 | -€2,056,776 | -€196,240 | +€1.9m | +90.5% |
| Operating profit (loss) | 9901 | -€2,755,458 | -€671,750 | +€2.1m | +75.6% |
| Financial income | 75/76B | €123,933 | €67,231 | -€56,702 | -45.8% |
| Recurring financial income | 75 | €123,933 | €67,231 | -€56,702 | -45.8% |
| Financial charges | 65/66B | €31,290 | €3,174 | -€28,116 | -89.9% |
| Recurring financial charges | 65 | €31,290 | €3,174 | -€28,116 | -89.9% |
| Profit (loss) for the period before taxes | 9903 | -€2,662,815 | -€607,693 | +€2.1m | +77.2% |
| Income taxes | 67/77 | €585 | €182 | -€403 | -68.9% |
| Profit (loss) for the period | 9904 | -€2,663,400 | -€607,875 | +€2.1m | +77.2% |
| Profit (loss) for the period to be appropriated | 9905 | -€2,663,400 | -€607,875 | +€2.1m | +77.2% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 17 October 2026 via checked.be.